Psoriatic arthritis (PsA) presents in up to 30% of patients with psoriasis (PsO) and may precede, occur concurrently with, or occur after the development of PsO. It is imperative to recognize that PsA can present in the dermatology or rheumatology clinic depending on the primary symptom and that clinicians then accurately diagnose PsA by utilizing screening questionnaires, as well as screening patients with PsA for common comorbidities.
The first episode of this CME Outfitters Snack series on the evolving treatment landscape for PsA features expert faculty describing clinically relevant pathophysiologic processes that contribute to the development of psoriatic arthritis in order to facilitate proper screening and faster diagnosis of patients with PsA.
At the end of this CME/CE activity, participants should be able to describe clinically relevant pathophysiologic processes that contribute to the development of psoriatic arthritis.
Supported by an educational grant from Bristol Myers Squibb Company.
Physicians, PAs, nurse practitioners, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.
Dr. Fernandez reports that he receives grants from Mallinckrodt and Novartis. He receives research support from AbbVie Inc.; Corbus Pharmaceuticals Holdings, Inc.; Mallinckrodt Pharmaceuticals; and Pfizer Inc. He is on the speakers bureau for AbbVie Inc.; Mallinckrodt Pharmaceuticals; and Novartis. He is a consultant for AbbVie Inc.; Alexion Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Mallinckrodt Pharmaceuticals; and Novartis.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Michael J. Franks, MSN, AGACNP-BC, FNP, BC (peer reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-029-H01-P
Call us at (877) CME-PROS or (877) 263-7767.